Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) Equity Ratio (2016 - 2025)

Macrogenics (MGNX) has disclosed Equity Ratio for 14 consecutive years, with 0.22 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 51.2% to 0.22 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.22, a 51.2% decrease, with the full-year FY2025 number at 0.22, down 51.2% from a year prior.
  • Equity Ratio was 0.22 for Q4 2025 at Macrogenics, up from 0.19 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.75 in Q2 2021 to a low of 0.19 in Q2 2025.
  • A 5-year average of 0.53 and a median of 0.54 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: increased 1.0% in 2023, then crashed 51.2% in 2025.
  • Macrogenics' Equity Ratio stood at 0.71 in 2021, then decreased by 29.16% to 0.51 in 2022, then increased by 1.0% to 0.51 in 2023, then dropped by 13.27% to 0.44 in 2024, then plummeted by 51.2% to 0.22 in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Equity Ratio are 0.22 (Q4 2025), 0.19 (Q2 2025), and 0.44 (Q4 2024).